GlassScriptPhysician profile
Hannah E Heiligman
NPI 1902438955
$5,777.15
in general payments reported to CMS, 2019-2025
32 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,318 · 2022: $1,078 · 2023: $1,050 · 2024: $1,166 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.42 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,527.89 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,088.43 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $655.82 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $406.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $270.73 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $239.92 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $232.11 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $196.09 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $169.40 | 2021-2024 | Belsomra, Steglatro, Capvaxive |
| Astellas Pharma US INC | $129.27 | 2021-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $88.13 | 2021-2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $84.02 | 2022-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $76.04 | 2023 | |
| Exact Sciences Corporation | $67.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $61.77 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.28 | 2023-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $55.05 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $54.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.93 | 2021 | |
| Corcept Therapeutics | $36.58 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $31.32 | 2021-2025 | Nexletol |
| Ascend Therapeutics US, LLC | $27.88 | 2022 | |
| Smith+Nephew, INC. | $27.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.73 | 2021 | |
| Amarin Pharma, INC. | $21.86 | 2021 | |
| Bausch Health US, LLC | $19.40 | 2024 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $19.28 | 2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $15.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.77 | 2022 | |
| Eisai INC. | $14.18 | 2021 | |
| Dexcom, INC. | $13.30 | 2024 | Dexcom G6 Transmitter |
| Lupin INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Heiligman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.